Ask about this productRelated genes to: CBLL1 Blocking Peptide
- Gene:
- CBLL1 NIH gene
- Name:
- Cbl proto-oncogene like 1
- Previous symbol:
- -
- Synonyms:
- HAKAI, FLJ23109, RNF188
- Chromosome:
- 7q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2003-07-21
- Date modifiied:
- 2016-04-26
Related products to: CBLL1 Blocking Peptide
Related articles to: CBLL1 Blocking Peptide
- This study investigates the role of N6-methyladenosine (m6A) regulators in osteoporosis (OP) and their interplay with the immune microenvironment, aiming to identify potential m6A-related biomarkers for OP risk assessment and treatment. - Source: PubMed
Publication date: 2026/04/14
Wang ZhenyangChen YongqinYang YuxuanXu BitengJiao XiejiaQi Lei - Over-activated M1 macrophages, which destroyed the balance of macrophage phenotype in the synovial microenvironment, play a pivotal role in rheumatoid arthritis (RA) progression. Increasing evidence indicates that mA RNA methylation serves as a crucial epigenetic regulatory mechanism in modulating the transition from M0 to M1 macrophages. Saposhnikovia divaricata (Turcz.) Schischk treats RA through immune regulation. In our previous study, chromones (CHR) from Saposhnikovia divaricata could alleviate RA by inhibiting the pathological manifestations of synovial inflammation, but the mechanism of action remains to be elucidated. - Source: PubMed
Publication date: 2026/04/08
Yang XuHao ZhichaoXu ShiqiBu GangtaoWang MinSun YanLi YuxinWang YiranChen QingshanZhang LiliKuang HaixueHuang LiliLiu Yan - : Metabolic dysfunction-associated steatotic liver disease (MASLD) is a globally prevalent condition with a complex pathogenesis. While both m6A RNA methylation regulators and gut microbiota have been independently implicated in MASLD, their potential causal interplay remains unexplored. This study aimed to investigate the causal relationships among m6A regulatory genes, gut microbiota, and MASLD, and to assess the mediating role of gut microbiota. : We performed a two-sample Mendelian randomization (MR) analysis using publicly available genome-wide association study (GWAS) data. Genetic instruments for m6A regulators were derived from blood expression quantitative trait loci (eQTL) data. Gut microbiota and MASLD data were obtained from large-scale metagenomic and disease GWAS, respectively. The inverse-variance weighted method was the primary analysis, supplemented by sensitivity and mediation analyses to evaluate potential mediating pathways. : Genetically predicted levels of four m6A regulators showed significant causal associations with MASLD risk: ALKBH3 increased risk (OR = 1.17), whereas ALKBH5 (OR = 0.89), CBLL1 (OR = 0.76), and RBM15B (OR = 0.83) were protective. Nineteen gut microbial taxa were causally linked to MASLD. Among these, seven taxa were influenced by the four identified m6A genes. Although no mediation effects reached strict statistical significance, the pathway from ALKBH5 to MASLD via Parabacteroides abundance showed a suggestive indirect effect accounting for 21.9% of the total effect ( = 0.068). Given the limited statistical power of mediation analyses in MR settings, this observation should be interpreted with caution and requires validation in larger, well-powered studies. : This MR study provides genetic evidence supporting causal roles of specific m6A regulators in MASLD and suggests that gut microbiota may partially mediate these relationships. The findings highlight a potential "m6A-gut microbiota-liver" axis in MASLD pathogenesis. - Source: PubMed
Publication date: 2026/03/11
Qiu DongmeiSuo LiweiWei TaoLu ZhenweiWeng QixinXiao JianxingWang XinchiXu QinyuWu Jingtong - N6-methyladenosine (m6A) RNA methylation, a pivotal epigenetic modification, has been implicated in the pathogenesis and progression of diverse diseases. This study sought to elucidate the functional contributions of m6A-related genes to the pathogenesis of chronic kidney disease (CKD) using a strategy that integrated machine learning and experimental validation, with the goal of identifying robust diagnostic biomarkers and novel molecular subtypes. - Source: PubMed
Publication date: 2026/02/02
Chen JiahengWang ZhiweiLiao YantingDing Wencong - The RNA modification N-methyladenosine (mA) plays a key role in RNA processing. It is catalysed by the RNA methyltransferase complex (MTC) which includes METTL3, METTL14 and CBLL1. Recently, a METTL3 inhibitor demonstrated promising preclinical results in several cancer types, yet the therapeutic potential of targeting mA in breast cancer (BCa) remains poorly understood. Utilising a large BCa cohort, we identified that increased METTL14 and CBLL1 expression was associated with a more favourable prognosis, whereas increased METTL3 expression was associated with poorer patient outcomes in Triple Negative BCa (TNBC). Using siRNA depletion, we identified distinct METTL3, METTL14 and CBLL1 regulated gene networks in BCa cell lines. METTL3 inhibition reduced proliferation and invasion of BCa cell lines and induced an immune activation transcriptional signature. These results provide insight into the clinical functions of METTL3, METTL14 and CBLL1 in BCa and support the therapeutic potential of targeting METTL3 in BCa, particularly in TNBC. - Source: PubMed
Publication date: 2025/11/27
Harris Anna ELothion-Roy JenniferThompson Rachel LHaque MariaWoodcock Corinne LAlsaleem Mansour ADean AlexanderKariri YousifToss Michael SGudas Lorraine JGreen Andrew RAllegrucci CinziaDavis Melissa BIrshad SheebaPark Kyong-HwaMadhusudan SrinivasanFray Rupert GJeyapalan Jennie NRutland Catrin SRakha Emad AMongan Nigel P